Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTT Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Metastatic Pancreatic Ductal Adenocarcinoma
NCT07745790Phase 2Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jul 2026
- Primary completion
- Jul 2029
- Countries
- 1
01
Overview
A Phase 2 trial of v941, sintilimab, tegafur in pancreatic ductal adenocarcinoma (PDAC), sponsored by Ruijin Hospital. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
v941sintilimabtegafur
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07745790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07745790.